Literature DB >> 1912991

Barbiturates inhibit ATP-K+ channels and voltage-activated currents in CRI-G1 insulin-secreting cells.

R Z Kozlowski1, M L Ashford.   

Abstract

1. Patch-clamp recording techniques were used to examine the effects of barbiturates upon the ATP-K+ channel, and voltage-activated channels present in the plasma membrane of CRI-G1 insulin-secreting cells. 2. Thiopentone inhibited ATP-K+ channel activity when applied to cell-attached patches or the intracellular or extracellular surface of cell-free patches. Secobarbitone and pentobarbitone were also effective inhibitors of ATP-K+ channels in cell-free patches, whereas phenobarbitone was ineffective. 3. The diabetogenic agent, alloxan, which is structurally related to the barbiturates also produced an inhibition of ATP-K+ channel activity in outside-out patches. 4. Whole-cell ATP-K+ currents were used to quantify the effects of the barbiturates: concentration-inhibition curves for thiopentone, secobarbitone and pentobarbitone resulted in IC50 values of 62, 250 and 360 microM respectively. Phenobarbitone at a concentration of 1 mM was virtually ineffective. 5. Calculation of the apparent membrane concentrations for these drugs indicate that for a given degree of ATP-K+ channel inhibition a similar concentration of each barbiturate is present in the membrane. This suggests that hydrophobicity plays a primary role in their mechanism of action. The pH-dependence and additive nature of barbiturate block also indicates a membrane site of action. 6. Thiopentone, (100 microM) was also found to inhibit differentially voltage-activated whole-cell currents. The relative potency of thiopentone at this concentration was 0.64, 0.38 and 0.12 for inhibiting Ca2+, K+ and Na+ currents respectively when compared with its ability to inhibit the ATP-K+ channel.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1912991      PMCID: PMC1908196          DOI: 10.1111/j.1476-5381.1991.tb12370.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  Effect of carbohydrates upon fluorescence of reduced pyridine nucleotides from perifused isolated pancreatic islets.

Authors:  U Panten; J Christians; E von Kriegstein; W Poser; A Hasselblatt
Journal:  Diabetologia       Date:  1973-12       Impact factor: 10.122

2.  Degenerate perturbations of protein structure as the mechanism of anaesthetic action.

Authors:  C D Richards; K Martin; S Gregory; C A Keightley; T R Hesketh; G A Smith; G B Warren; J C Metcalfe
Journal:  Nature       Date:  1978 Dec 21-28       Impact factor: 49.962

3.  Barbiturate enhancement of spike frequency adaptation in Aplysia giant neurons.

Authors:  K L Zbicz; W A Wilson
Journal:  J Pharmacol Exp Ther       Date:  1981-04       Impact factor: 4.030

4.  Barbiturate interaction with phosphatidylcholine.

Authors:  R F Novak; T J Swift
Journal:  Proc Natl Acad Sci U S A       Date:  1972-03       Impact factor: 11.205

5.  Calcium and pancreatic beta-cell function. I. Stimulatory effects of pentobarbital on insulin release.

Authors:  B Hellman
Journal:  Biochim Biophys Acta       Date:  1977-05-26

6.  Differences between the actions of thiopental and pentobarbital in squid giant axons.

Authors:  C Sevcik
Journal:  J Pharmacol Exp Ther       Date:  1980-09       Impact factor: 4.030

7.  Effect of pentobarbital on Na and Ca action potentials in an invertebrate neuron.

Authors:  J M Goldring; M P Blaustein
Journal:  Brain Res       Date:  1982-05-27       Impact factor: 3.252

8.  Barbiturate reduction of calcium-dependent action potentials: correlation with anesthetic action.

Authors:  E J Heyer; R L Macdonald
Journal:  Brain Res       Date:  1982-03-18       Impact factor: 3.252

9.  Accelerating effects of pentobarbitone on the inactivation process of the calcium current in Helix neurones.

Authors:  K Nishi; Y Oyama
Journal:  Br J Pharmacol       Date:  1983-07       Impact factor: 8.739

10.  Two distinct interactions of barbiturates and chlormethiazole with the GABAA receptor complex in rat cuneate nucleus in vitro.

Authors:  N L Harrison; M A Simmonds
Journal:  Br J Pharmacol       Date:  1983-10       Impact factor: 8.739

View more
  7 in total

1.  Severe hyperkalemia induced by a short interruption of barbiturate coma.

Authors:  Eleni E Magira; Konstantinos Sakellaridis; Paraskeui Tselioti; Barbara Grammatikopoulou; Athanasios Prekates
Journal:  Intensive Care Med       Date:  2010-11-10       Impact factor: 17.440

Review 2.  ATP-regulated K+ channel in mitochondria: pharmacology and function.

Authors:  A Szewczyk; A Czyz; G Wojcik; L Wojtczak; M J Nalecz
Journal:  J Bioenerg Biomembr       Date:  1996-04       Impact factor: 2.945

3.  Antiarrhythmic drugs, clofilium and cibenzoline are potent inhibitors of glibenclamide-sensitive K+ currents in Xenopus oocytes.

Authors:  H Sakuta; K Okamoto; Y Watanabe
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

4.  Effect of MgATP on pinacidil-induced displacement of glibenclamide from the sulphonylurea receptor in a pancreatic beta-cell line and rat cerebral cortex.

Authors:  M Schwanstecher; C Brandt; S Behrends; U Schaupp; U Panten
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

5.  Mg(2+)-dependent inhibition of KATP by sulphonylureas in CRI-G1 insulin-secreting cells.

Authors:  K Lee; S E Ozanne; C N Hales; M L Ashford
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

6.  Effects of chemical modification of amino and sulfhydryl groups on KATP channel function and sulfonylurea binding in CRI-G1 insulin-secreting cells.

Authors:  K Lee; S E Ozanne; C N Hales; M L Ashford
Journal:  J Membr Biol       Date:  1994-05       Impact factor: 1.843

7.  Lipophilicity predicts the ability of nonsulphonylurea drugs to block pancreatic beta-cell KATP channels and stimulate insulin secretion; statins as a test case.

Authors:  Joana Real; Caroline Miranda; Charlotta S Olofsson; Paul A Smith
Journal:  Endocrinol Diabetes Metab       Date:  2018-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.